Treatment
 |
File Format: Microsoft PowerPoint (.ppt) | File Size: 876 KB
|
 |
Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease.
File Format: Microsoft PowerPoint (.ppt) | File Size: 2.09 MB
|
|
The safety profile and virologic, biochemical, and clinical efficacy outcomes were similar among patients treated with 48 weeks of tenofovir/emtricitabine, tenofovir monotherapy, or entecavir monotherapy in this randomized phase II study.
|
 |
Downloadable slides for use in your own noncommercial presentations highlight key data on selecting patients for HBV screening and evaluation and optimizing first-line treatment.
File Format: Microsoft PowerPoint (.ppt) | File Size: 2.13 MB
|
|
A multivariate analysis identified cirrhosis, older age, and male sex as independent predictors of hepatocellular carcinoma incidence in patients receiving at least 12 months of oral antiviral therapy, most of which was lamivudine based.
|
|
Intrahepatic cccDNA levels at baseline were not prognostic for response to peginterferon alfa-2a plus adefovir therapy.
|
|
Virologic response rates with entecavir were highest among patients who were previously untreated and among those with HBeAg-negative disease or low baseline HBV DNA levels; high response rates were also observed among patients with precore mutations.
|
 |
More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later.
File Format: Microsoft PowerPoint (.ppt) | File Size: 270 KB
|
|
Natalie H. Bzowej, MD, PhD, discusses the strengths and limitations of the study by Buster and colleagues that suggests that HBeAg loss within 32 weeks of peginterferon-based therapy could be an early predictor of response.
|
 |
Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis.
File Format: Microsoft PowerPoint (.ppt) | File Size: 2.04 MB
|
|
Featured Content
Capsule Summaries and Expert Highlights of key liver disease data from the 2009 meeting.
Review expert faculty commentaries on the most clinically relevant new hepatitis journal articles.
Enhance your ability to apply AASLD’s 2009 HCV Practice Guidelines through interactive activities.
|
|